Amgen (AMGN) Tops Q3 EPS by 41c, FY Guidance Tops Consensus

Amgen (NASDAQ: AMGN) reported Q3 EPS of $4.67, $0.41 better than the analyst estimate of $4.26. Revenue for the quarter came in at $6.71 billion versus the consensus estimate of $6.69 billion.

GUIDANCE:

Amgen sees FY2021 EPS of $16.50-$17.10, versus the consensus of $16.43. Amgen sees FY2021 revenue of $25.8-26.2 billion, versus the consensus of $26 billion.

For earnings history and earnings-related data on Amgen (AMGN) click here.

You May Also Be Interested In

• Freightos Limited (CRGO) Tops Q2 EPS by 3c ; Offers Guidance
• Benchmark Reiterates Buy Rating on Odysight.AI Inc. (ODYS)
• InspireMD (NSPR) Tops Q2 EPS by 1c